Log in

NASDAQ:VRCAVerrica Pharmaceuticals Stock Price, Forecast & News

-0.18 (-2.63 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $6.66
50-Day Range
MA: $9.68
52-Week Range
Now: $6.66
Volume137,273 shs
Average Volume228,987 shs
Market Capitalization$171.89 million
P/E RatioN/A
Dividend YieldN/A
Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company was founded in 2013 and is headquartered in West Chester, Pennsylvania.
Read More
Verrica Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:VRCA



Sales & Book Value

Annual SalesN/A
Book Value$1.88 per share


Net Income$-28,210,000.00


Market Cap$171.89 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
-0.18 (-2.63 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

How has Verrica Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VRCA stock has decreased by 36.7% and is now trading at $6.66.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Verrica Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Verrica Pharmaceuticals

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Verrica Pharmaceuticals

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) issued its earnings results on Wednesday, August, 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.07.
View Verrica Pharmaceuticals' earnings history

What price target have analysts set for VRCA?

5 brokers have issued 1 year price targets for Verrica Pharmaceuticals' stock. Their forecasts range from $10.00 to $18.00. On average, they expect Verrica Pharmaceuticals' stock price to reach $15.00 in the next year. This suggests a possible upside of 125.2% from the stock's current price.
View analysts' price targets for Verrica Pharmaceuticals

Has Verrica Pharmaceuticals been receiving favorable news coverage?

Media coverage about VRCA stock has been trending very positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Verrica Pharmaceuticals earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Verrica Pharmaceuticals

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,040,000 shares, an increase of 25.2% from the July 15th total of 830,400 shares. Based on an average daily volume of 95,300 shares, the short-interest ratio is currently 10.9 days. Currently, 8.1% of the shares of the company are short sold.
View Verrica Pharmaceuticals' Current Options Chain

Who are some of Verrica Pharmaceuticals' key competitors?

What other stocks do shareholders of Verrica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include AbbVie (ABBV), Gilead Sciences (GILD), Aurora Cannabis (ACB), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Pfizer (PFE), Progenics Pharmaceuticals (PGNX), Exxon Mobil (XOM), Allergan (AGN) and Agile Therapeutics (AGRX).

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:
  • Mr. Ted White, Pres, CEO & Director (Age 54)
  • Mr. Chris Degnan, Chief Financial Officer (Age 39)
  • Mr. Joe Bonaccorso, Chief Commercial Officer (Age 55)
  • Dr. Patrick Burnett M.D., Ph.D., Chief Medical Officer (Age 47)
  • Christopher G. Hayes, Sec.

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Kornitzer Capital Management Inc. KS (1.90%), Creative Planning (0.08%), Spouting Rock Asset Management LLC (0.06%) and UBS Group AG (0.03%). Company insiders that own Verrica Pharmaceuticals stock include Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White.
View institutional ownership trends for Verrica Pharmaceuticals

Which institutional investors are selling Verrica Pharmaceuticals stock?

VRCA stock was sold by a variety of institutional investors in the last quarter, including Spouting Rock Asset Management LLC, and UBS Group AG.
View insider buying and selling activity for Verrica Pharmaceuticals

Which institutional investors are buying Verrica Pharmaceuticals stock?

VRCA stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning, and Kornitzer Capital Management Inc. KS. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Linda Palczuk, Paul B Manning, Sean Stalfort, and Ted White.
View insider buying and selling activity for Verrica Pharmaceuticals

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $6.66.

How big of a company is Verrica Pharmaceuticals?

Verrica Pharmaceuticals has a market capitalization of $171.89 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.